Yu Hongliang, Gu Dayong, He Xia, Gao Xianshu, Bian Xiuhua
Department of Radiation Oncology, Jiangsu Cancer Hospital affiliated with Nanjing Medical University, Nanjing, People's Republic of China.
Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, People's Republic of China.
Onco Targets Ther. 2016 Jan 5;9:159-70. doi: 10.2147/OTT.S96983. eCollection 2016.
Whether the addition of induction chemotherapy (IC) or adjuvant chemotherapy (AC) to concurrent chemoradiotherapy (CCRT) is superior to CCRT alone for locally advanced nasopharyngeal cancer is unknown. A Bayesian network meta-analysis was performed to investigate the efficacy of CCRT, IC + CCRT, and CCRT + AC on locally advanced nasopharyngeal cancer. The overall survival (OS) with hazard ratios (HRs) and locoregional recurrence rates (LRRs) and distant metastasis rates (DMRs) with risk ratios (RRs) were investigated. After a comprehensive database search, eleven studies involving 2,626 assigned patients were included in this network meta-analysis. Compared with CCRT alone, IC + CCRT resulted in no significant improvement in OS or LRR and a marginal improvement in DMR (OS: HR =0.67, 95% credible interval (CrI) 0.32-1.18; LRR: RR =1.79, 95% CrI 0.80-3.51; DMR: RR =1.79, 95% CrI 0.24-1.04) and CCRT + AC exhibited no beneficial effects on any of the endpoints of OS, LRR, or DMR (OS: HR =0.99, 95% CrI 0.64-1.43; LRR: RR =0.78, 95% CrI 0.43-1.32; DMR: RR =0.85, 95% CrI 0.57-1.24). As a conclusion, for locally advanced nasopharyngeal cancer, no significant differences in the treatment efficacies of CCRT, IC + CCRT, and CCRT + AC were found, with the exception of a marginally significant improvement in distant control observed following IC + CCRT compared with CCRT alone.
对于局部晚期鼻咽癌,在同步放化疗(CCRT)基础上联合诱导化疗(IC)或辅助化疗(AC)是否优于单纯CCRT尚不清楚。进行了一项贝叶斯网络荟萃分析,以研究CCRT、IC + CCRT和CCRT + AC对局部晚期鼻咽癌的疗效。研究了总生存(OS)的风险比(HRs)以及局部区域复发率(LRRs)和远处转移率(DMRs)的风险比(RRs)。经过全面的数据库检索,该网络荟萃分析纳入了11项研究,涉及2626例分配患者。与单纯CCRT相比,IC + CCRT在OS或LRR方面无显著改善,在DMR方面有轻微改善(OS:HR = 0.67,95%可信区间(CrI)0.32 - 1.18;LRR:RR = 1.79,95% CrI 0.80 - 3.51;DMR:RR = 1.79,95% CrI 0.24 - 1.04),且CCRT + AC在OS、LRR或DMR的任何终点上均未显示出有益效果(OS:HR = 0.99,95% CrI 0.64 - 1.43;LRR:RR = 0.78,95% CrI 0.43 - 1.32;DMR:RR = 0.85,95% CrI 0.57 - 1.24)。结论是,对于局部晚期鼻咽癌,CCRT、IC + CCRT和CCRT + AC的治疗效果无显著差异,但与单纯CCRT相比,IC + CCRT在远处控制方面有轻微显著改善。